ReviewFrontiers in medicine2021
Management of Sjögren's Syndrome: Present Issues and Future Perspectives.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Efficacy of topical mesenchymal stem cell exosome in Sjögren's syndrome-related dry eye: a randomized clinical trial.BMC ophthalmology · 2025Trial
- Beyond Dryness: Mapping the Psychological and Cognitive Burden in Sjögren's Disease-A Narrative Review.Journal of clinical medicine · 2026Review
- An Unusual Case of Primary Sjögren's Syndrome and Lymphangioleiomyomatosis Diagnosed From Refractory Cough.Cureus · 2025Article
- Neurological involvement in primary Sjögren's syndrome: a retrospective analysis of clinical, radiological, laboratory and therapeutic correlations.BMJ neurology open · 2025Article
- Efficacy of Cevimeline on Xerostomia in Sjögren's Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Current therapeutic research, clinical and experimental · 2025Review
- Targeted Therapy for Severe Sjogren's Syndrome: A Focus on Mesenchymal Stem Cells.International journal of molecular sciences · 2024Review
- Diagnostic and therapeutic potentials of extracellular vesicles for primary Sjögren's Syndrome: A review.Dentistry review (New York, N.Y.) · 2024Article
- Laboratory features and pharmacological management of early and late-onset primary Sjögren's syndrome.Rheumatology international · 2024Article
- Therapeutic Targets in the Management of Dry Eye Disease Associated with Sjögren's Syndrome: An Updated Review of Current Insights and Future Perspectives.Journal of clinical medicine · 2024Review
- Estimated prevalence, incidence and healthcare costs of Sjögren's syndrome in France: a national claims-based study.RMD open · 2024Article
- Multidimensional immunotherapy for dry eye disease: current status and future directions.Frontiers in ophthalmology · 2024Review
- Chronic constrictive pericarditis: a rare cardiac involvement in primary Sjögren's syndrome.BMC cardiovascular disorders · 2023Article
- Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).Journal of clinical and translational hepatology · 2023Article
- A Pilot Study of a Panel of Ocular Inflammation Biomarkers in Patients with Primary Sjögren's Syndrome.Current issues in molecular biology · 2023Article
- Raman spectroscopy combined with a support vector machine algorithm as a diagnostic technique for primary Sjögren's syndrome.Scientific reports · 2023Article
- Inhibitory Effects of Extracellular Vesicles from iPS-Cell-Derived Mesenchymal Stem Cells on the Onset of Sialadenitis in Sjögren's Syndrome Are Mediated by Immunomodulatory Splenocytes and Improved by Inhibiting miR-125b.International journal of molecular sciences · 2023Article
- Article
- Sjögren syndrome: looking forward to the future.Therapeutic advances in musculoskeletal disease · 2022Review
- Identification of diagnostic markers related to fecal and plasma metabolism in primary Sjögren's syndrome.American journal of translational research · 2022Article
- [Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].Zhonghua nei ke za zhi · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In view of the new possibilities for the treatment of primary Sjögren's syndrome (pSS) given by the availability of new biotechnological agents targeting the various molecular and cellular actors of the pathological process of the disease, classification criteria aimed at selecting patients to be enrolled in therapeutic trials, and validated outcome measures to be used as response criteria to these new therapies, have been developed and validated in the last decades. Unfortunately, the therapeutic trials so far completed with these new treatments have yielded unsatisfactory or only partially positive results. The main issues that have been evoked to justify the poor results of the new therapeutic attempts are: (i) the extreme variability of the disease phenotypes of the patients enrolled in the trials, which are dependent on different underlying patterns of biological mechanisms, (ii) the fact that the disease has a long indolent course, and that most of the enrolled patients might already have irreversible clinical features. The advances in the research of new disease biomarkers that can better distinguish the different clinical phenotypes of patients and diagnose the disease in an earlier phase are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.